top of page
Coronavirus Update
Cancer52 is already a virtual organisation and has run under this business model for a number of years, only bringing people together to...
Getting a Better Deal for Rare and Less Common Cancers - One Year on from the NHS Long Term Plan
Working with our members, Cancer52 has looked at the progress that has been made for people with rare and less common cancers against the...
Summary of Cancer52 / PHE Event: Development in Data for Rare and Less Common Cancers
Cancer52 and PHE/NCRAS are delighted to be able to share a film and a report of the very successful Developments in Data for Rare and...
‘Getting a better deal for people with rare and less common cancers: what we can learn from patients
On Wednesday 10th July we launched a new report, ‘Getting a better deal for people with rare and less common cancers: what we can learn...
What the National Data Opt-out means for cancer patients
Cancer52, together with use MY data, have jointly produced a briefing document on what The National Data Opt-out means for cancer...
Cancer52 in the New Statesman
We are delighted that Cancer52 features in this month's New Statesman's Oncology Supplement, published to coincide with this year's...
Cancer52 Trustee Recruitment
We are pleased to announce that Cancer52 is recruiting trustees to its board to support the future development and growth of the...
Cancer52 film on PHE website
In June, at the PHE Cancer Services, Data and Outcomes Conference 2018, Cancer52 worked with the National Cancer Registration and...
Getting a better deal for people with rare and less common cancers: the next ten years
We're excited to announce the publication of our new briefing document 'Getting a better deal for people with rare and less common...
The UK team has crossed the finish line of the C2C4C challenge!
Yesterday afternoon, the Bristol-Myers Squibb (BMS) UK team cycled into Uxbridge, marking the end of this year’s Country 2 Country 4...
bottom of page